AZ presents strong H1 financial results
The sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza.
Read More
Tag: quarter
GSK Q2 figures boosted by vaccine sales
The company has readjusted its prediction for its earnings per share to decline in the range of -3% to -5% at CER, as opposed to the previous -5% to -9%.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
